Comparison of Acceleromyography and Electromyography in Obese Patients Undergoing General Anesthesia
ConditionObesity
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-65
SponsorUniversity of Padova
About this trial
The goal of this prospective observational study is to compare two different methods of monitoring muscle relaxation during anesthesia - acceleromyography (AMG) and electromyography (EMG) - in people with obesity who are having bariatric surgery with general anesthesia and the muscle relaxant rocuronium.
The main question is: Which method is more accurate and precise in measuring the Train-of-Four (TOF) ratio during surgery? As part of this comparison, researchers will also note how quickly each method detects recovery of muscle function after the reversal drug sugammadex.
Participants will:
* Receive standard anesthesia care for bariatric surgery, including rocuronium to relax the muscles. * Have two small monitoring devices applied, one to each hand: AMG on one hand, EMG on the other. * Be monitored for muscle function during surgery and after receiving sugammadex to reverse the muscle relaxation.
Researchers will also record how easy each device is to use and whether participants have any breathing problems after surgery.
Eligibility criteria
Qualifiers
Adults aged 18-65 years
Pathological obesity (Class II with comorbidities or Class III)
Scheduled for bariatric surgery under general anesthesia
Written informed consent obtained
Disqualifiers
Severe acute or chronic respiratory disease (e.g., asthma, COPD, severe restrictive disease)
Severe acute or recent cardiac disease (e.g., acute or recent myocardial infarction, inducible ischemia, heart failure)
End-stage hepatic or renal disease
Intolerance, allergy, or contraindication to study-related drugs
Trial design
Treatments tested in this trial
- Neuromuscular monitoring with electromyography (EMG)
- Neuromuscular monitoring with acceleromyography (AMG)
Treatment groups
30 Participants
are divided into 1 treatment groupSponsors and collaborators
University of Padova
Lead sponsor
University Hospital, Padua, Italy
Collaborator
Source ClinicalTrials.gov